| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a92803f6cf472da3edb056e6ddcf5fb5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2833 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate |
2010-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd98a2300c1159d3d584e6c7da8186f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_016ecb6da6d42751ad249d9b5ed59347
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21078ccfdf280d10a732d8babb3d3704 |
| publicationDate |
2019-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2766505-C |
| titleOfInvention |
T cell receptors |
| abstract |
A T cell receptor (TCR) having the property of binding to the gp100 YLEPGPVTA peptide-HLA-A2 complex and comprising a TCR alpha variable domain and/or a TCR beta variable domain, characterized in that: (i) said TCR is mutated relative to a TCR having the extracellular alpha and beta chain sequences SEQ ID Nos: 2 and 3 in its alpha chain variable domain amino acids 1 to 109 of SEQ ID No: 2 and/or its beta chain variable domain amino acids 1 to 112 of SEQ ID No: 3; and (ii) said alpha variable domain has at least 90% sequence identity to the amino acid sequence 1 to 109 of SEQ ID No: 2, and/or said beta variable domain has at least 90% sequence identity to the amino acid sequence 1 to 1 12 of SEQ ID No: 3; and (iii) said TCR has a binding affinity for, and/or a binding half-life for, the YLEPGPVTA-HLA-A2 complex at least double that of a reference TCR, the said reference TCR having the extracellular alpha chain sequence SEQ ID No: 45 and the extracellular beta chain sequence SEQ ID No: 46. The use of such TCRs in adoptive therapy, and fusions of such TCRs with therapeutic agents are also described. |
| priorityDate |
2009-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |